We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IVBXF market cap is 7.8B. The company's latest EPS is CNY -0.6335 and P/E is -7.59.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 1.05B | 3.84B | 4.27B | 4.56B | 6.21B |
| Operating Income | -1.78B | -426.5M | -2.66B | -3.03B | -1.58B |
| Net Income | -1.72B | -998.42M | -2.73B | -2.18B | -1.03B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 7.23B | 11.83B | 16.24B | 17.59B | 20.63B |
| Total Liabilities | 2.47B | 3.06B | 5.91B | 6.86B | 8.1B |
| Total Equity | 4.76B | 8.78B | 10.33B | 10.73B | 12.53B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -1.66B | -307.69M | -2.02B | -1.92B | 147.81M |
| Investing | -2.57B | -5.18B | -2.7B | -1.44B | -998.66M |
| Financing | 2.11B | 4.91B | 5B | 2.89B | 2.59B |
| Market Cap | 7.8B |
| Price to Earnings Ratio | -7.59 |
| Price to Sales Ratio | 1.26 |
| Price to Cash Ratio | 0.78 |
| Price to Book Ratio | 0.62 |
| Dividend Yield | - |
| Shares Outstanding | 1.62B |
| Average Volume (1 week) | 9.49k |
| Average Volume (1 Month) | 4.57k |
| 52 Week Change | 18.18% |
| 52 Week High | 6.41 |
| 52 Week Low | 3.55 |
| Spread (Intraday) | 0.66 (13.12%) |
| Company Name | Innovent Biologics Inc (PK) |
| Address |
maples corporate services limited grand cayman KY1-1104 |
| Website | https://www.innoventbio.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
